Financial Performance - Revenue for Q3 2023 reached ¥116,205,291.50, an increase of 5.37% year-over-year[5] - Net profit attributable to shareholders decreased by 13.76% to ¥15,350,384.64 in Q3 2023[5] - Basic earnings per share fell by 35.31% to ¥0.1418[5] - Total operating revenue for Q3 2023 reached CNY 340,680,063.30, a slight increase of 0.7% compared to CNY 334,444,793.33 in the same period last year[19] - Net profit for Q3 2023 was CNY 66,554,829.52, a decrease of 3.4% from CNY 68,865,809.13 in Q3 2022[20] - The total comprehensive income for the third quarter was CNY 66,554,829.52, a decrease from CNY 68,865,809.13 in the previous period, representing a decline of approximately 3.8%[21] - Basic and diluted earnings per share for the period were CNY 0.6705, down from CNY 0.8481 in the previous period, indicating a decrease of about 21%[21] Assets and Liabilities - Total assets as of September 30, 2023, amounted to ¥1,451,888,670.00, a 122.75% increase compared to the end of the previous year[5] - The total assets of the company reached CNY 1,451,888,670.00, a substantial increase from CNY 651,789,219.99 year-on-year[18] - The total liabilities decreased slightly to CNY 130,795,207.70 from CNY 132,061,203.18 in the previous year[18] - Total current assets reached ¥1,072,689,877.91, significantly up from ¥282,267,007.37 at the start of the year[16] - Owner's equity increased significantly to CNY 1,321,093,462.30, compared to CNY 519,728,016.81 in the same period last year, marking a growth of 154%[18] Cash Flow - Cash flow from operating activities showed a significant decline of 74.90%, totaling ¥18,837,983.45 year-to-date[5] - Cash inflow from operating activities totaled CNY 287,307,555.61, compared to CNY 237,694,325.25 in the previous period, reflecting an increase of approximately 20.9%[22] - The net cash flow from operating activities was CNY 18,837,983.45, significantly lower than CNY 75,040,665.23 in the previous period, a decrease of about 75.1%[22] - Cash inflow from financing activities was CNY 782,943,530.00, with a net cash flow from financing activities of CNY 741,725,637.86, a significant improvement from -CNY 1,456,000.00 in the previous period[22] - The cash and cash equivalents at the end of the period amounted to CNY 327,921,221.93, up from CNY 110,744,626.87 in the previous period, representing an increase of approximately 195%[22] Expenses - Research and development expenses increased by 88.13% to ¥29,830,782.38 for the first nine months of 2023[10] - Research and development expenses increased significantly to CNY 29,830,782.38, compared to CNY 15,856,630.93 in the previous year, reflecting a growth of 88%[19] - The company experienced a 159.07% increase in sales expenses, totaling ¥45,425,247.33 for the first nine months of 2023[10] - The company reported a decrease in sales expenses to CNY 45,425,247.33 from CNY 17,533,823.75, indicating a strategic shift in cost management[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,382[13] - The largest shareholder, Linuo Investment Holdings, holds 34.39% of shares, totaling 37,240,000 shares, with 18,000,000 shares pledged[13] - The top ten shareholders collectively hold a significant portion of the company's equity, with the largest shareholder holding over 34%[13] - The company has no preferred shareholders as of the reporting period[15] Investment Activities - Investment activities resulted in a net cash outflow of ¥581,719,915.74, a 1,957.39% increase in outflow compared to the previous year[11] - Cash outflow from investment activities was CNY 712,880,085.37, a substantial increase from CNY 28,398,601.81 in the previous period[22] - The net cash flow from investment activities was -CNY 581,719,915.74, compared to -CNY 28,274,612.96 in the previous period, indicating a worsening of investment cash flow[22] Market and Product Development - The company has not reported any new product launches or technological advancements in this quarter[15] - There are no indications of market expansion or mergers and acquisitions in the current report[15] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[20] Audit Status - The third quarter report was not audited, indicating that the financial figures are subject to further verification[23]
科源制药(301281) - 2023 Q3 - 季度财报